Loading...
The FDA on Friday approved the serotonin-norepinephrine inhibitor Pristiq (desvenlafaxine) for the treatment of major depression. The drug is a metabolite of the antidepressant Effexor (venlafaxine).
Wyeth says Pristiq offers advantages over Effexor — namely, it can be started at the therapeutic dose rather than requiring a lead-in dose, and it's not metabolized by the liver, so there is less risk for drug-drug interactions. Skeptics, however, say that the drug appears to be no more effective than Effexor, and one expert suggests to the New York Times that it's a simply a way of extending the financial rewards of the predecessor drug, whose patents will begin to expire this year.
The manufacturer is also seeking approval of Pristiq for treatment of hot flashes associated with menopause. However, according to the Wall Street Journal, the FDA has requested additional research before approving Pristiq for that indication.
Comment
LINK(S):
Wall Street Journal story (Free)
New York Times story (Free)
Journal Watch Women's Health summary of study of desvenlafaxine for hot flashes (Subscription required)